JP2026016543A5 - - Google Patents
Info
- Publication number
- JP2026016543A5 JP2026016543A5 JP2025178768A JP2025178768A JP2026016543A5 JP 2026016543 A5 JP2026016543 A5 JP 2026016543A5 JP 2025178768 A JP2025178768 A JP 2025178768A JP 2025178768 A JP2025178768 A JP 2025178768A JP 2026016543 A5 JP2026016543 A5 JP 2026016543A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- sequence numbers
- treg
- antigen recognition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1912515.2 | 2019-08-30 | ||
| GBGB1912515.2A GB201912515D0 (en) | 2019-08-30 | 2019-08-30 | Engineered regulatory T cell |
| JP2022513373A JP2022546457A (ja) | 2019-08-30 | 2020-08-28 | 改変された制御性t細胞 |
| PCT/GB2020/052076 WO2021038249A1 (en) | 2019-08-30 | 2020-08-28 | Engineered regulatory t cell |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513373A Division JP2022546457A (ja) | 2019-08-30 | 2020-08-28 | 改変された制御性t細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026016543A JP2026016543A (ja) | 2026-02-03 |
| JP2026016543A5 true JP2026016543A5 (cg-RX-API-DMAC7.html) | 2026-05-21 |
Family
ID=68207135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513373A Pending JP2022546457A (ja) | 2019-08-30 | 2020-08-28 | 改変された制御性t細胞 |
| JP2025178768A Pending JP2026016543A (ja) | 2019-08-30 | 2025-10-23 | 改変された制御性t細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513373A Pending JP2022546457A (ja) | 2019-08-30 | 2020-08-28 | 改変された制御性t細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230134301A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021484A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022546457A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220051390A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114585730A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020338290A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3148676A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201912515D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290830A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021038249A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202217541D0 (en) * | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| EP4442322A1 (en) | 2023-04-06 | 2024-10-09 | Medizinische Hochschule Hannover | Liver-specific car for use against immunologic rejection |
| CN118001381B (zh) * | 2024-01-24 | 2025-04-22 | 首都医科大学附属北京地坛医院 | 一种药物组合物及应用 |
| WO2026027876A1 (en) * | 2024-07-29 | 2026-02-05 | Quell Therapeutics Limited | Chimeric antigen receptor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP2523686A2 (en) * | 2010-01-14 | 2012-11-21 | Glaxo Group Limited | Liver targeting domain antibodies |
| GB201108236D0 (en) * | 2011-05-17 | 2011-06-29 | Ucl Business Plc | Method |
| CN105713881B (zh) * | 2014-12-04 | 2019-12-06 | 科济生物医药(上海)有限公司 | 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用 |
| CA2974998C (en) * | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| WO2017021911A1 (en) * | 2015-08-04 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CA3042179A1 (en) * | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| CN111684061B (zh) * | 2018-01-19 | 2024-07-30 | 美天施生物科技有限两合公司 | 表达嵌合抗原受体的调节性t细胞 |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
-
2019
- 2019-08-30 GB GBGB1912515.2A patent/GB201912515D0/en not_active Ceased
-
2020
- 2020-08-28 KR KR1020227010359A patent/KR20220051390A/ko active Pending
- 2020-08-28 US US17/639,056 patent/US20230134301A1/en active Pending
- 2020-08-28 EP EP20767594.3A patent/EP4021484A1/en active Pending
- 2020-08-28 CA CA3148676A patent/CA3148676A1/en active Pending
- 2020-08-28 AU AU2020338290A patent/AU2020338290A1/en active Pending
- 2020-08-28 WO PCT/GB2020/052076 patent/WO2021038249A1/en not_active Ceased
- 2020-08-28 JP JP2022513373A patent/JP2022546457A/ja active Pending
- 2020-08-28 CN CN202080072135.2A patent/CN114585730A/zh active Pending
-
2022
- 2022-02-23 IL IL290830A patent/IL290830A/en unknown
-
2025
- 2025-10-23 JP JP2025178768A patent/JP2026016543A/ja active Pending